江苏省规模以上医药企业自主创新能力研究——基于创新价值链视角

On the independent innovation capability of pharmaceutical enterprises of Jiangsu Province from the perspective of innovation value chain

以江苏省规模以上医药制造企业为研究对象,通过两阶段数据包络分析方法考察江苏省规模以上医药制造企业自主创新能力,并利用Tobit回归模型实证分析影响江苏省规模以上医药制造企业自主创新能力的影响因素。结果表明:(1)江苏省规模以上医药制造企业2012、2013、2014年平均开发效率仅为0.239,平均成果转化率为0.741;(2)从创新价值链的角度看,江苏省绝大多数地区是低开发效率高成果转化效率;(3)Tobit回归结果来看,地区、工业总产值、引进技术的消化吸收经费支出和政府支持力度对企业自主创新能力影响较为显著。整体来看,江苏省规模以上医药制造企业的自主创新效率较低,仍有提升空间,可以借助地区和引进技术的消化吸收等手段提高企业自主创新能力。

Based on the relevant data of abovedesignated size pharmaceutical manufacturing enterprises,in Jiangsu Province,with two-stage data envelopment analysis method,it analyze and evaluate the independent innovation capability of pharmaceutical manufacturing industry in Jiangsu Province.The results show that:(1)The average R&D efficiencyof large-scale pharmaceutical manufacturing enterprises in 2012,2013 and 2014 was only 0.239,and the average conversion rate was 0.741.(2)From the perspective of innovative value chain,the R&D efficiency of most region in Jiangsu province is low,while the conversion efficiency is high.(3)According to the Tobit regression analysis results,theregions,gross industrial output value and other factors have a significant impact on the capability of independent R&D of enterprises.As a whole,the pharmaceutical manufacturing enterprises above designated size in Jiangsu Province are less efficient in independent R&D and there is still capabilities to improve.We can improve the capability of R&Dthrough the influence factors such as the technology digestion and absorption of R&D.